Sun's FDA Warning Letter

Share this article:
How serious is India's pharma problem?
Sun's FDA Warning Letter

The FDA has given generics maker Sun Pharmaceutical an earful, and publication of its seven-page May 7 Warning Letter—which characterizes the list of infractions as “not intended to be an all-inclusive list of violations and deviations” shows just some of the faults the US regulator has found at a manufacturing site in Gujarat, India.

Sun—and now-subsidiary Ranbaxy—have been a growing source of tension for reasons that include manufacturing problems that have triggered recalls, FDA manufacturing site bans, and claims by officials that India has been unfairly picked on by US regulatory authorities.

The May 7 letter provides insight as to some of the issues the FDA wants ironed out, which could come under the broad heading of don't destroy documents or try to hide unfavorable information.

Among the issues: failure to ensure lab records included complete data, deleting data files and declaring samples that did not meet FDA requires as “unofficial tests,” as well as reporting only good testing data as “official” from a sample batch.

FDA inspectors also found about 10 garbage bags filled with partially destroyed manufacturing documentation. This is in addition to finding partially destroyed corrective action documentation as well as Sun's failure to train staff about proper practices.

The FDA says Sun's attempts to investigate issues such as file deletion have been inadequate; that the company has failed not only to explain the negative testing results it uncovered but also “to justify the basis of your decision to invalidate the original failing.”

This is in addition to finding “three partially filled unidentified bags...in your firm's raw material warehouse,” and the fact that employees “were unable to determine conclusively the identity or status of the material.”

The regulator's letter notes that this is not the first time Sun has seen these complaints. The FDA notes that the firm's initial response, as well as those of January 28, 2014, and March 11, 2014, “lack sufficient corrective actions.”

The FDA said it may continue to ban drugs manufactured at the site if Sun fails to fix things according to the FDA's requirements.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.